



SuperGen to Present Data at EORTC-NCI-AACR

DUBLIN, Calif., Oct. 15 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present five posters at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" on October 23 and 24, 2008.

SuperGen's presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776 and SGI-1252. All presentations will occur as poster presentations.

Abstract Number/Title	Date
Abstract 403: Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial	Oct 23
Abstract 332: In vivo activity of SGI-1776, an orally active Pim kinase inhibitor	Oct 23
Abstract 426: Effects of food on the single-dose pharmacokinetics of oral MP-470 capsules	Oct 23
Abstract 480: MP-470, a novel multi-targeted tyrosine kinase inhibitor targeting RAD 51 is not toxic to human primary marrow stem cells at clinically relevant concentrations	Oct 24
Abstract 571: Modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a potent small molecule JAK2 inhibitor	Oct 24

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit <http://www.supergen.com>.

Contacts:

SuperGen, Inc.
Timothy L. Enns
SVP, Corporate Communications
& Business Development
Tel: (925) 560-0100
Email: tenns@supergen.com

Mary M. Vegh
Manager, Investor Relations
Tel: (925) 560-2845
E-mail: mary.vegh@supergen.com

Dorland Global Public Relations
Michael Beckerich (Media)
Tel: (212) 677-7632
mbeckerich@dorland.com

